Log in to search using one of your social media accounts:

 

Midatech files CTA for MTD201 ’s carcinoid cancer and acromegaly trial

UK-based specialist pharmaceutical firm Midatech Pharma has submitted a clinical trial application (CTA) for its drug candidate MTD201 to treat carcinoid cancer and acromegaly.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion. While diagnostic and therapeutic methods have advanced, little information exists on trends in acromegaly characteristics over time. The Liège Acromegaly Survey (LAS) Database, a relational database, is designed to assess the profile of acromegaly patients at diagnosis and during long-term follow-up at multiple treatment centers. The following results were obtained at diagnosis. The study population consisted of 3173 acromegaly patients from ten countries; 54.5% were female. Males were significantly younger at diagnosis than females ...
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Research Source Type: research
It is debated if acromegalic patients have an increased risk to develop malignancies. The aim of the present study was to assess the standardized incidence ratios (SIRs) of different types of cancer in acromegaly on a large series of acromegalic patients managed in the somatostatin analogs era. It was evaluated the incidence of cancer in an Italian nationwide multicenter cohort study of 1512 acromegalic patients, 624 men and 888 women, mean age at diagnosis 45 ± 13 years, followed up for a mean of 10 years (12573 person-years) in respect to the general Italian population. Cancer was diagnosed in 124 patients, 72 wom...
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Research Source Type: research
Cancers, Vol. 9, Pages 103: Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review Cancers doi: 10.3390/cancers9080103 Authors: Ryuya Yamanaka Eisuke Abe Toshiteru Sato Azusa Hayano Yasuo Takashima Pituitary adenomas are often treated with radiotherapy for the management of tumor progression or recurrence. Despite the improvement in cure rates, patients treated by radiotherapy are at risk of development of secondary malignancies. We conducted a comprehensive literature review of the secondary intracranial tumors that occurred following radiotherapy to pituitary aden...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Summary Cervical cancer is an important public health problem. Pap smear is the leading strategy of screening programs for cervical cancer worldwide. However, delayed diagnosis leads to more aggressive and less effective treatments. Patients with uterine cervix malignancies who are referred for radiotherapy have advanced-stage disease, which results in high rates of locoregional recurrence. The use of radiotherapy as a treatment for cervical cancer causes morphological changes in neoplastic and non-neoplastic epithelial cells, as well as in stromal cells, which make it difficult to diagnose the residual lesion, resulting i...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
AbstractPurposeAcromegaly is a disease associated with an increased risk for several kinds of neoplasms including colon and thyroid cancer. Although the association between acromegaly and pancreatic neoplasms has not been elucidated, it has recently been reported thatGNAS gene mutations were found in 58% of intraductal papillary mucinous neoplasms (IPMNs), which are representative pancreatic cystic lesions, suggesting a link between IPMNs and acromegaly. To assess the prevalence of pancreatic cystic lesions in patients with acromegaly, we performed a retrospective cross-sectional single institute study.MethodsThirty consec...
Source: Pituitary - Category: Endocrinology Source Type: research
This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: Case Report Source Type: research
Conclusions:Our case presented only 2 years after radiotherapy suggesting this toxicity can be an earlier complication that clinicians should be aware of.Disclosure: Dr. Shaikh has nothing to disclose. Dr. kumthekar has nothing to disclose. Dr. Raizer has received personal compensation for activities with Genentech/Roche, Abbvie, Stemline, Foundation Medicine, Novocure, Proximagene, Bristol-Meyers Squibb, and Aurasense as a speaker and advisory board member. Dr. Raizer has received research support from Genentech, Plexxikon, Novartis, Ziopharm, and Celldex. Dr. dixit has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Tags: Neurologic Complications of Cancer Source Type: research
CONCLUSIONS: According to our results thyroid lesions were significantly more common in patients with acromegaly; in case of TC the difference was not significant. The updated meta-analysis showed significantly increased prevalence of both disorders. In conclusion, systematic thyroid examination should be an important part of follow-up in case of acromegalic patients. (Endokrynol Pol 2017; 68 (1): 2-6). PMID: 28255974 [PubMed - in process]
Source: Endokrynologia Polska - Category: Endocrinology Authors: Tags: Endokrynol Pol Source Type: research
ConclusionsMalignant neoplasms are significantly more common in patients with acromegaly. Particularly, risk of thyroid cancer was increased over fivefold. Systematic screening for neoplastic diseases should be important part of follow-up in these patients. Further case –control studies are strongly indicated to evaluate which neoplasms are more common in acromegalic patients and what is the exact risk of malignancy.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
Acromegaly has traditionally been regarded as a monomorphous disorder resulting from a benign pituitary adenoma. Increasing evidence, however, is highlighting that this disorder is associated with a spectrum of morphologically distinct pituitary tumors with variable clinical, biochemical and radiologic features and differing therapeutic outcomes that are attributed to different genetic and epigenetic changes. These data underscore the need for developing a more refined clinicopathological risk stratification system and implementing personalized targeted therapeutic approaches.
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Commentary Source Type: research
More News: Acromegaly | Cancer | Cancer & Oncology | Clinical Trials | Pharmaceuticals